Pyxis Oncology recap highlights MICVO Phase 1 results and target lifts
Pyxis Oncology reported MICVO Phase 1 results in HNSCC, with 36% confirmed responses, 94% disease control, median PFS of 6.2 months and 12-month OS of 79%, alongside analyst price-target lifts and CEO appointment of Thomas Civik as permanent CEO.